注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Arcus Biosciences Inc是一家臨床階段的生物製藥公司,專注於開發癌症療法。該公司的六款在研產品正處於臨床開發階段,其分子是一種抗TIGIT抗體,正在進行兩項III期註冊研究。該公司的差異化聯合療法正在開髮用於治療多種大型腫瘤類型,包括肺癌、結直腸癌、前列腺癌和胰腺癌。該公司的臨床開發管線包括Domvanalimab、AB308、Etrumadenant、Quemliclustat、Zimberelimab和AB521。Domvanalimab是其Fc沉默的抗TIGIT單克隆抗體。 AB308是其具有Fc功能的抗TIGIT單克隆抗體。Etrumadenant旨在抑制由A2a和A2b受體介導的腫瘤浸潤淋巴細胞和骨髓細胞(樹突狀細胞、巨噬細胞)的腺苷驅動損傷。Quemliclustat是一種非常有效和選擇性的小分子CD73抑製劑。Zimberelimab是其抗PD-1抗體。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Michael Quigley | - | 2021 | Director |
Antoni Ribas | 57 | 2019 | Independent Director & Member of Scientific Advisory Board |
Jeffrey A. Bluestone | 71 | - | Chairman of Scientific Advisory Board |
Kathryn E. Falberg | 63 | 2017 | Independent Director |
David L. Lacey | 72 | 2020 | Independent Director & Member of Scientific Advisory Board |
C. Patrick Machado | 60 | 2019 | Independent Director |
Yasunori Kaneko | 71 | 2015 | Lead Independent Director |
Merdad V. Parsey | 60 | 2020 | Director |
Stefani Spranger | - | 2020 | Member of Scientific Advisory Board |
Andrew J. Perlman | 76 | 2020 | Independent Director |
Nicole Lambert | 50 | 2021 | Independent Director |
Johanna Mercier | 53 | 2024 | Director |
Linda Slanec Higgins | 62 | 2021 | Member of Scientific Advisory Board & Director |
K. Christopher Garcia | - | - | Co-Founder & Member of Scientific Advisory Board |
Terry J. Rosen | 64 | 2015 | Co-Founder, Chairman & CEO |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核